Lupin receives approval from USFDA for Bromfenac Ophthalmic Solution
Bromfenac Ophthalmic Solution, 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain
Bromfenac Ophthalmic Solution, 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain
The receipt of this permission paves way for the launch of Olaparib film coated tablets in India
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market
Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide
The Oradox brand introduced a range of revolutionary products designed to elevate the standard of oral care
Dapagliflozin Tablets (RLD Farxiga) had estimated annual sales of USD 7282 million in the US
Pitavastatin Tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
Subscribe To Our Newsletter & Stay Updated